Showing results (1311-1320 of 1,887) with videos related to
Sort By:
Pageof 189
The British Journal of Dermatology|April 4, 2017
Comparative effectiveness of biological therapies on improvements in quality of life in patients with psoriasisI Y K Iskandar, D M Ashcroft, R B Warren, et al.Redox Biology|April 28, 2015
A potential role for endogenous proteins as sacrificial sunscreens and antioxidants in human tissuesSarah A Hibbert, Rachel E B Watson, Neil K Gibbs, et al.Conservation Genetics Resources|May 2, 2020
A Galaxy-based bioinformatics pipeline for optimised, streamlined microsatellite development from Illumina next-generation sequencing dataSarah M Griffiths, Graeme Fox, Peter J Briggs, et al.Gut|April 29, 2009
Polymorphisms in E-cadherin (CDH1) result in a mis-localised cytoplasmic protein that is associated with Crohn's diseaseA M Muise, T D Walters, W K Glowacka, et al.The British Journal of Dermatology|November 20, 2008
Outcomes of methotrexate therapy for psoriasis and relationship to genetic polymorphismsR B Warren, R L Smith, E Campalani, et al.The British Journal of Dermatology|February 3, 2009
How not to get scar(r)ed: pointers to the correct diagnosis in patients with suspected primary cicatricial alopeciaM J Harries, R M Trueb, A Tosti, et al.Inflammatory Bowel Diseases|August 27, 2009
Assessing disease activity in ulcerative colitis: patients or their physicians?Dan Turner, Anne M Griffiths, David Mack, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|October 11, 2023
Implementing well-being in the management of psoriasis: An expert recommendationRachel Sommer, Ulrich Mrowietz, Kristian Gaarn Du Jardin, et al.Global Change Biology|January 28, 2021
Carbon flux and forest dynamics: Increased deadwood decomposition in tropical rainforest tree-fall canopy gapsHannah M Griffiths, Paul Eggleton, Nicole Hemming-Schroeder, et al.Journal of the American Academy of Dermatology|September 21, 2011
Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trialsMark Lebwohl, Craig Leonardi, Christopher E M Griffiths, et al.Pageof 189